Cytokinetics gets an ‘incremental’ win for delayed heart drugnews2025-05-13T15:06:19+00:00May 13th, 2025|Endpoints News|
TIGIT graveyard expands as GSK drops late-stage asset with iTeosnews2025-05-13T13:37:31+00:00May 13th, 2025|Endpoints News|
#EASL25: Vir’s hep B disappointment, new data on Ipsen’s Iqirvonews2025-05-12T15:08:32+00:00May 12th, 2025|Endpoints News|
Lilly says further head-to-head trial data back Zepbound over Novo’s Wegovynews2025-05-12T11:08:07+00:00May 12th, 2025|Endpoints News|
Trump confirms ‘most favored nation’ drug price plansnews2025-05-12T01:51:50+00:00May 12th, 2025|Endpoints News|
Revolution’s KRAS drugs appear competitive in several lung cancer settingsnews2025-05-09T15:11:24+00:00May 9th, 2025|Endpoints News|
Corvus’ Phase 1 atopic dermatitis data prompt stock rallynews2025-05-09T10:57:33+00:00May 9th, 2025|Endpoints News|
CRISPR isn’t living up to its potential. Two scientists have a plan to fix thatnews2025-05-08T14:00:20+00:00May 8th, 2025|Endpoints News|
Lantheus culls late-stage Lilly-partnered prostate cancer radioligandnews2025-05-08T10:38:37+00:00May 8th, 2025|Endpoints News|
Gilead reveals plans to put another $11B into US manufacturingnews2025-05-07T19:38:02+00:00May 7th, 2025|Endpoints News|
